Potentiation of anticancer agents by new synthetic isoprenoids. II. Inhibition of the growth of transplantable murine tumors.
The antitumor effects of combinations of synthetic isoprenoids-decaprenylamine.HCl, N-(p-methylbenzyl)decaprenylamine.HCl [N-(PMB)-decaprenylamine.HCl], and decaprenoic acid-with anticancer agents were studied in male ICR mice with ascites sarcoma 180 (S180) and in male BALB/c mice with fibrosarcoma Meth A. Decaprenylamine.HCl, N-(PMB)-decaprenylamine.HCl, and decaprenoic acid were tested in combination with bleomycin A2 (BLM) on S180. Decaprenoic acid was also examined in combination with BLM or 5-fluorouracil (FUra) for effects on fibrosarcoma Meth A. The dosages of synthetic isoprenoids used in the combination therapy were much below the median lethal dose. In the low-dosage schedule, decaprenylamine.HCl, N-(PMB)-decaprenylamine.HCl or decaprenoic acid considerably enhanced the antitumor effect of BLM on S180; e.g., the T/C value (mean survival time of treated mice/mean survival time of controls) for decaprenylamineHCl plus BLM, N-(PMB)-decaprenylamine.HCl plus BLM, or decaprenoic acid plus BLM was 294, 357, and 279% respectively, and the combinations increased life-span 2.4-fold, 2.3-fold, or 1.8-fold, respectively, as compared to the effects of BLM alone. The combination of BLM or FUra with decaprenoic acid, when administered by iv injection to mice with fibrosarcoma Meth A (solid tumor system), did not produce synergism. However, a preventive effect of decaprenoic acid monotherapy was observed: Decaprenoic acid at 3 mg/kg resulted in 38.9% suppression of tumor growth 21 days after inoculation.
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001761:Bleomycin / Q000633:toxicity; D004317:Doxorubicin / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D005354:Fibrosarcoma / Q000473:pathology*; D005472:Fluorouracil / Q000633:toxicity; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D012510:Sarcoma 180 / Q000473:pathology*; D013329:Structure-Activity Relationship; D013729:Terpenes / Q000633:toxicity*
D000970:Antineoplastic Agents; C043082:N-(4-methylbenzyl)decaprenylamine; D013729:Terpenes; D001761:Bleomycin; C043083:decaprenylamine; D004317:Doxorubicin; C043081:decaprenoic acid; D005472:Fluorouracil